Amit Dutt

About

Dr. Amit Dutt, Professor at the University of Delhi South Campus, is a leading expert in cancer genomics, previously heading research at ACTREC, Tata Memorial Centre. With a dual PhD degree from ICGEB, Delhi and Univ of Zurich, Switzerland and postdoctoral work at t he Broad Institute of Harvard and MIT, his research integrates genome-wide analyses and functional studies to identify genetic drivers of cancer and investigate microbial roles in cancer. His laboratory focuses on understanding the somatic changes that occur in human cancer cells and how these changes can help develop the next generation of effective targeted therapies to improve the treatment of cancer patients. The group specifically focuses on the genomic features of genetic alterations underlying oncogenesis and cancer progression in the lung, breast, cervical, gallbladder, head and neck, and others cancers. The efforts involve using advanced sequencing methodologies followed by functional validation to study the implications of genetic alterations in identifying novel cancer dependencies, therapeutic strategies, and biomarkers.

Dr Dutt is a recipient of the Swiss National Science Foundation fellowship award; the Julius Klaus Foundation award from the University of Zurich; the Ramalingaswami Fellowship Award from the Department of Biotechnology (DBT); the Wellcome Trust/ DBT India Alliance Intermediate Fellowship Award; YIM Boston Young Scientist Award; Outstanding Alumni award from JMI, and the Shanti Swarup Bhatnagar Award in the field of Medical Sciences 2017.

Employment

• Department of Genetics, University of Delhi South Campus Professor
  2024 - Present
• Tata Memorial Centre Scientist G/ Princpal Investigator
  2010 - 2024
• Broad Institute Postdoctoral Research Associate
  2005 - 2010

Education

• Life Science Zurich Ph.D
  2000 - 2004
• International Center for Genetic Engineering and Biotechnology Ph.D
  1998 - 2000

Projects & Funding

Projects & funding information is unavailable.

Publications (116)

• CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer
  British Journal of Cancer 2026 DOI: 10.1038/s41416-026-03388-z
  +Save
• Genomic characterization of AI resistance in hormone receptor-positive breast cancer using LTED cell line models
  Biochemical and Biophysical Research Communications 2025 0 citations DOI: 10.1016/j.bbrc.2025.152450
  +Save
• Comprehensive Genomic Profiling of Anaplastic Thyroid Cancer Identifies Alterations in THRA, a Potential Modifier of Cellular Plasticity
  JCO Global Oncology 2025 DOI: 10.1200/GO-24-00610
  +Save
• Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing
  NPJ Systems Biology and Applications 2025 DOI: 10.1038/s41540-025-00536-8
  +Save
• Genomic Characterization of Papillary Thyroid Cancer Reveals Germline Mutations Associated With Congenital Hypothyroidism
  JCO Global Oncology 2025 DOI: 10.1200/GO-25-00043
  +Save
• The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer
  ESMO Open 2025 DOI: 10.1016/j.esmoop.2025.104479
  +Save
• Inhibition of PERK mediated UPR acts as a switch for reversal of residual senescence and as senolytic therapy in glioblastoma.
  Neuro-oncology 2024 31 citations DOI: 10.1093/neuonc/noae134
  +Save
• Uniqueness of lung cancer in Southeast Asia.
  The Lancet regional health. Southeast Asia 2024 39 citations DOI: 10.1016/j.lansea.2024.100430
  +Save
• Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment.
  Molecular cancer research : MCR 2024 5 citations DOI: 10.1158/1541-7786.mcr-23-0265
  +Save
• RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer.
  JCO precision oncology 2024 8 citations DOI: 10.1200/po.23.00622
  +Save